

Warner Chilcott

[View the current Warner Chilcott Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10947-Warner+Chilcott.html)

(<http://www.bioportfolio.com/biocorporate/10947-Warner+Chilcott.html>)

Contact Details:

100 Enterprise Drive

Rockaway

NJ

07866

United States of America

Tel: (973) 442-3200

Fax: (973) 442-3283

Email:

Warner Chilcott is a leading specialty pharmaceutical company focused on developing, manufacturing and marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the United States. We have established strong franchises in these two areas through our precision marketing techniques and specialty sales forces of approximately 400 representatives. We believe that our proven product development capabilities, coupled with our ability to execute acquisitions and in-licensing transactions and develop partnerships, such as our relationship with LEO Pharma A/S, will enable us to sustain and grow these franchises. Our franchises are comprised of complementary portfolios of established branded, development stage and new products, including our recently launched products, Loestrin® 24 Fe and Taclonex®. Our women's healthcare franchise is anchored by our strong presence in the hormonal contraceptive and hormone therapy categories and our dermatology franchise is built on our established positions in the markets for psoriasis and acne therapies. In April 2006, we launched Loestrin® 24 Fe, an oral contraceptive with a novel patented 24-day dosing regimen, with the goal of growing the market share position we have achieved with our Ovcon® and Estrostep® products in the hormonal contraceptive market. We also have a significant presence in the hormone therapy market, primarily through our products femhrt® and Estrace® Cream. In dermatology, our psoriasis product Dovonex® enjoys the leading position in the United States for the non-steroidal topical treatment of psoriasis. We strengthened and extended our position in the market for psoriasis therapies with the April 2006 launch of Taclonex® the first once-a-day topical psoriasis treatment that combines betamethasone dipropionate, a corticosteroid, with calcipotriene, the active ingredient in Dovonex®. Our product Doryx® is the leading branded oral tetracycline in the United States for the treatment of acne. In 2005, we launched Doryx® delayed-release tablets.

Recent Publications by Warner Chilcott:



- [Safety of doxycycline and minocycline: a systematic review.](#)

OBJECTIVE: The goal of this review was to summarize the available...14th November, 2006
 Warner Chilcott Laboratories,- Clin Ther. 2005 Sep;27(9):1329-42. ([DOI Direct Link](#))

Press Releases on Warner Chilcott:

The Cystic Fibrosis Foundation to Benefit from Holiday Film Promotion	24th November, 2009	Cystic Fibrosis Foundation	<i>Warner Home Video and CVS/pharmacy to Donate Proceeds from Holiday DVD Sales BETHESDA, Md., Nov. 24 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation announced today that CVS/pharmacy and</i>
PROFNET EXPERT ALERTS: New Mammogram Guidelines	18th November, 2009		<i>TOPIC ALERT New Mammogram Guidelines (33 responses) EXPERT ALERTS 1. Law: Challenge of Jackson Estate's Executor Selection May Be Too Late 2. Law: New Law</i>
Democratic Senators Discuss Reforms for Small Business Health Care	18th November, 2009	U.S. Senate Committee on Small Business & Entrepreneurship	<i>WASHINGTON, Nov. 18 /PRNewswire-USNewswire/ -- Five Democratic Senators today gave back-to-back speeches on the Senate floor discussing the need to focus on small businesses when considering health</i>
Democratic Senators to Discuss Reforms for Small Business Health Care	18th November, 2009	U.S. Senate Committee on Small Business & Entrepreneurship	<i>THIS MORNING five Democratic Senators will give back-to-back speeches on the Senate floor morning to discuss how exchanges will help increase competition and lower the cost of health care for small</i>
Warner Chilcott Announces Secondary Equity Offering	13th November, 2009	Warner Chilcott plc	<i>ARDEE, Ireland, Nov. 13 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced a 20,000,000 share secondary offering of its ordinary shares by certain selling shareholders. The</i>

BioNews Results for Warner Chilcott



- [Warner Chilcott Prices Secondary Equity Offering](#)
BioSpace: Nov 21 2009 12:38AM Matching: warner chilcott
- [Warner Chilcott Prices Secondary Equity Offering](#)
TickerTech.com: Nov 20 2009 9:33AM Matching: warner chilcott
- [Warner Chilcott Prices Secondary Equity Offering](#)
SmartBrief: Nov 20 2009 3:36PM Matching: warner chilcott
- [Intensive refresher course in pediatrics for physicians preparing for certification examination](#)
News-Medical.Net: Nov 19 2009 7:11PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments On Boehringer Ingelheim Clinical Test Results In Treatment Of Female Sexual](#)
Medical News Today: Nov 18 2009 8:43AM Matching: warner chilcott
- [BioSante Pharmaceuticals Hails Boehringer Ingelheim Efforts to Treat Female Sexual Dysfunction](#)
TradingMarkets: Nov 18 2009 4:18AM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction](#)
Web Newswire: Nov 16 2009 9:28PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinica...](#)
Zibb: Nov 16 2009 6:48PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual](#)
Street Insider: Nov 16 2009 6:00PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of...](#)
Forbes.com: Nov 16 2009 5:58PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction](#)
Business Wire UK: Nov 16 2009 5:49PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual](#)
Business Wire via Yahoo!: Nov 16 2009 5:48PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction](#)
FinanzNachrichten.de: Nov 16 2009 5:46PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual](#)
Business Wire: Nov 16 2009 5:44PM Matching: warner chilcott
- [BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual](#)
Yahoo! Canada: Nov 16 2009 5:41PM Matching: warner chilcott

Warner Chilcott Clinical Trials:



- [Study of Safety and Efficacy of an Oral Contraceptive](#)



Warner Chilcott Patents:

- 7572779- [Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation](#)
- 7569560- [Extended cycle multiphasic oral contraceptive method](#)
- 7485319- [Doxycycline metal complex in a solid dosage form](#)
- 7067505- [Di-steroidal prodrugs of estradiol](#)
- 7067504- [Di-steroidal prodrugs of ethinyl estradiol](#)
- 6962908- [Oral pharmaceutical products containing 17 .beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation](#)
- 6521247- [Dual iron containing nutritional supplement](#)
- 6495177- [Orally dissolvable nutritional supplement](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

